US 11,911,387 B2
Vasoprotective and cardioprotective antidiabetic therapy
Thomas Klein, Radolfzell (DE); Andreas Daiber, Scheesel (DE); Odd-Erik Johansen, Hoevik (NO); Michael Mark, Biberach an der Riss (DE); Sanjaykumar Patel, Twickenham (GB); and Hans-Juergen Woerle, Munich (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Dec. 15, 2020, as Appl. No. 17/122,072.
Application 14/669,813 is a division of application No. 13/295,174, filed on Nov. 14, 2011, granted, now 9,034,883, issued on May 19, 2015.
Application 17/122,072 is a continuation of application No. 15/668,819, filed on Aug. 4, 2017, abandoned.
Application 15/668,819 is a continuation of application No. 14/669,813, filed on Mar. 26, 2015, abandoned.
Claims priority of provisional application 61/492,391, filed on Jun. 2, 2011.
Claims priority of provisional application 61/421,400, filed on Dec. 9, 2010.
Claims priority of provisional application 61/415,545, filed on Nov. 19, 2010.
Claims priority of application No. 10191261 (EP), filed on Nov. 15, 2010; application No. 11168317 (EP), filed on May 31, 2011; and application No. 11170992 (EP), filed on Jun. 22, 2011.
Prior Publication US 2021/0121468 A1, Apr. 29, 2021
Int. Cl. A61K 31/522 (2006.01); C07D 473/06 (2006.01); C07D 473/12 (2006.01); A61K 31/397 (2006.01); A61K 31/5377 (2006.01); A61K 31/616 (2006.01); A61K 31/727 (2006.01); A61K 31/785 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01); A61K 31/519 (2006.01); A61K 31/155 (2006.01); A61K 31/4184 (2006.01)
CPC A61K 31/522 (2013.01) [A61K 31/155 (2013.01); A61K 31/397 (2013.01); A61K 31/4184 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/616 (2013.01); A61K 31/727 (2013.01); A61K 31/785 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01); C07D 473/06 (2013.01); C07D 473/12 (2013.01)] 3 Claims
 
1. A method for slowing the progression of, or treating diabetic nephropathy in a patient who does not adequately respond to therapy with an angiotensin receptor blocker (ARB), said method comprising administering a therapeutically effective amount of linagliptin, optionally in combination with one or more other therapeutic substances to the patient, wherein the method comprises administering a therapeutically effective amount of linagliptin in combination with an ARB.